on Pharnext (EPA:ALPHA)
Adjustment of the nominal value at Pharnext
The biopharmaceutical company Pharnext SCA, specializing in the development of therapies for neurodegenerative diseases, announced a capital reduction by reducing the par value of its shares. According to the decision taken at the General Meeting of June 30, 2023, the par value per share increases from 0.10 euros to 0.05 euros, thus reducing the share capital from 188,168.20 euros to 94,084.10 euros.
This change comes in a context of losses and follows the 9th resolution approved by the shareholders.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pharnext news